I am Miranda from Shenzhen, China, and I’m delighted to meet everyone on this flawless forum. I work as a technician at Uray Biotech, mainly developing enzymes for Sanger sequencing, including BDT, POP7, Hi-Di, and others. My greatest achievement so far has been developing a BDT specifically for hairpin (HP) structures—it can easily handle all HP samples during sequencing. I’m very happy to discuss with everyone the various challenges and issues encountered in Sanger sequencing.
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM